Brief: Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301
07/01/2025 13:03
Jan 7 (Reuters) - Cingulate Inc CING.O :
* CINGULATE INC: FINAL STUDY COMPLETED FOR CINGULATE'S LEAD
ASSET
CTX-1301
* CINGULATE INC: NO SERIOUS ADVERSE EVENTS REPORTED
* CINGULATE INC: SUBMISSION OF NEW DRUG APPLICATION TARGETED
FOR
MID 2025
Source text: ID:nGNX95Hjxz
Further company coverage: CING.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)